Wilde, A.-C.B.; Greverath, L.M.; Steinhagen, L.M.; de Chamorro, N.W.; Leicht, E.; Fischer, J.; Herta, T.; Berg, T.; Preuss, B.; Klein, R.;
et al. Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. J. Clin. Med. 2022, 11, 681.
https://doi.org/10.3390/jcm11030681
AMA Style
Wilde A-CB, Greverath LM, Steinhagen LM, de Chamorro NW, Leicht E, Fischer J, Herta T, Berg T, Preuss B, Klein R,
et al. Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine. 2022; 11(3):681.
https://doi.org/10.3390/jcm11030681
Chicago/Turabian Style
Wilde, Anne-Christin Beatrice, Lena Maria Greverath, Lara Marleen Steinhagen, Nina Wald de Chamorro, Elise Leicht, Janett Fischer, Toni Herta, Thomas Berg, Beate Preuss, Reinhild Klein,
and et al. 2022. "Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis" Journal of Clinical Medicine 11, no. 3: 681.
https://doi.org/10.3390/jcm11030681
APA Style
Wilde, A.-C. B., Greverath, L. M., Steinhagen, L. M., de Chamorro, N. W., Leicht, E., Fischer, J., Herta, T., Berg, T., Preuss, B., Klein, R., Tacke, F., & Müller, T.
(2022). Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 11(3), 681.
https://doi.org/10.3390/jcm11030681